Search

Author/Creator Dompeling, Ellen C

1. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Issue 6 (June 2022)

Authors:
Kater, Arnon P; Levin, Mark-David; Dubois, Julie; Kersting, Sabina; Enggaard, Lisbeth; Veldhuis, Gerrit J; Mous, Rogier; Mellink, Clemens H M; van der Kevie-Kersemaekers, Anne-Marie F; Dobber, Johan A; Poulsen, Christian B; Frederiksen, Henrik; Janssens, Ann; Schjødt, Ida; Dompeling, Ellen C; Ran...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 6(2022)
Page Start:
818
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Issue 3 (March 2022)

Authors:
Kersting, Sabina; Dubois, Julie; Nasserinejad, Kazem; Dobber, Johan A; Mellink, Clemens; van der Kevie-Kersemaekers, Anne-Marie F; Evers, Ludo M; de Boer, Fransien; Koene, Harry R; Schreurs, John; van der Klift, Marjolein; Velders, Gerjo A; van der Spek, Ellen; van der Straaten, Hanneke M; Hoogen...
Journal:
Lancet
Issue:
Volume 9:Issue 3(2022)
Page Start:
e190
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search